Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)

Podobne zapisy

• PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
  od: Lu, P, i wsp.
  Wydane: (2013)
• Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
  od: De Benedetti, Fabrizio, i wsp.
  Wydane: (2012)
• Polyarticular juvenile idiopathic arthritis (pJIA): clinical and serologic predictors of inactive disease (ID)
  od: Meiorin, Silvia
  Wydane: (2014)
• 2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
  od: Yokota S, i wsp.
  Wydane: (2008-09-01)
• 2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
  od: Yokota, S, i wsp.
  Wydane: (2008)